Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer
Melita A. Gordon(University of Liverpool), Jennifer K. Richer(University of Colorado Anschutz Medical Campus), Julia Wulfkuhle(University of California, San Francisco), Beatrice Babbs(University of Colorado Anschutz Medical Campus), Nicholas C. D’Amato(Vaxart (United States)), Kathleen C. Torkko(University of Colorado Anschutz Medical Campus), Rosa I. Gallagher(George Mason University), Anthony Elias(University of Colorado Cancer Center), Bolin Liu(Huazhong University of Science and Technology), Emanuel F. Petricoin(Center for Biologics Evaluation and Research), Ting Dong(ZheJiang Institute For Food and Drug Control), Haihua Gu(Ministry of Education of the People's Republic of China)
Cited by 61
Related Papers
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|1.6k
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
|JAMA Oncology|2020|707
Differential Gene Regulation by the Two Progesterone Receptor Isoforms in Human Breast Cancer Cells
|Journal of Biological Chemistry|2002|574
NCCN Guidelines Insights: Breast Cancer, Version 1.2017
|Journal of the National Comprehensive Cancer Network|2017|544